Zobrazeno 1 - 10
of 251
pro vyhledávání: '"van Hout, BA"'
Autor:
Malottki, K 1, Lawson, R 2, Beecroft, S 3, Van Hout, BA 3, Heaton, D 3, Starita, C 2, Patel, S 2
Publikováno v:
In Value in Health December 2022 25(12) Supplement:S448-S448
Autor:
Durno, N 1, Heisen, M 2, Penton, H 2, Schmid, R 3, Ethgen, O 4, Szilvasy, Z 5, Friedel, E 6, Wong, O 7, Charman, T 8, San José Cáceres, A 9, Mühlbacher, AC 10, Van Hout, BA 11, Brazier, JE 11, Stolk, E 12
Publikováno v:
In Value in Health December 2022 25(12) Supplement:S444-S444
Publikováno v:
In Value in Health December 2022 25(12) Supplement:S423-S423
Publikováno v:
Transfusion, 52(3), 478-488. Wiley-Blackwell Publishing Ltd
BACKGROUND: During the past decade, blood screening tests such as triplex nucleic acid amplification testing (NAT) and human T-cell lymphotropic virus type I or I (HTLV-I/II) antibody testing were added to existing serologic testing for hepatitis B v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::4a0f221f5af4ba1aed9d08cdb9679cd1
https://pure.eur.nl/en/publications/c1418e95-4a36-4500-8b08-a0e5d0800cde
https://pure.eur.nl/en/publications/c1418e95-4a36-4500-8b08-a0e5d0800cde
Autor:
Borkent-Raven, BA, Janssen, MP, van der Poel, CL, Schaasberg, WP, Bonsel, Gouke, van Hout, BA (Ben)
Publikováno v:
Vox Sanguinis, 99(1), 54-64. Wiley-Blackwell Publishing Ltd
Background Transfusion recipient data are needed for correct estimation of cost-effectiveness in terms of recipient outcomes after transfusion. Also, such data are essential for monitoring blood use, estimation of future blood use and benchmarking. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::d9b1fa8afe02646b08dbd87174581dbb
https://pure.eur.nl/en/publications/31c8d40f-7299-47cf-89ee-e1a48d509a07
https://pure.eur.nl/en/publications/31c8d40f-7299-47cf-89ee-e1a48d509a07
Autor:
Ong, ATL (Andrew), Daemen, Joost, van Hout, BA (Ben), Lemos, PA, Bosch, Joke, van Domburg, Ron, Serruys, PWJC (Patrick)
Publikováno v:
European Heart Journal. Supplement, 27, 2996-3003. Oxford University Press
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::61600762ec57f45591ff576b88c89e2e
https://pure.eur.nl/en/publications/299f0ffa-6b27-4cf9-935d-7407b08b49cd
https://pure.eur.nl/en/publications/299f0ffa-6b27-4cf9-935d-7407b08b49cd
Autor:
van Hout Ba
Publikováno v:
Scandinavian journal of gastroenterology. Supplement. (239)
Taking the right decision in health care may be as much an art as a science. However, without exception and whatever the decision, usage is made of scarce resources and they may be used in an alternative way. This implies costs and there comes a time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::981fd22a1e2568e19d4ceaf83e78db00
https://pubmed.ncbi.nlm.nih.gov/14743876
https://pubmed.ncbi.nlm.nih.gov/14743876
Publikováno v:
Nederlands Tijdschrift voor Geneeskunde, 148, 975-978. Bohn Stafleu van Loghum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::9bf4f53485575488f7ec92e140659a4c
https://pure.eur.nl/en/publications/cac866a5-e0f9-474a-ba01-34cc9c8abf6f
https://pure.eur.nl/en/publications/cac866a5-e0f9-474a-ba01-34cc9c8abf6f
Publikováno v:
Alimentary Pharmacology & Therapeutics, 17(10), 1237-1245. Wiley
Background: Proton pump inhibitors have a prominent role in the management of acid-related diseases. Controlling expenses on proton pump inhibitors would yield great economic benefits for Dutch health care. Aim: To investigate whether clinical differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::ac4b85734dd33e9f652e85fa96da9469
https://research.rug.nl/en/publications/82f3951c-73ef-4f5a-9968-403d75bc847f
https://research.rug.nl/en/publications/82f3951c-73ef-4f5a-9968-403d75bc847f
Publikováno v:
Clinical Therapeutics, 25(2), 635-646. Elsevier
Background: The focus of treatment of patients with peptic ulcer or gastroesophageal reflux disease has changed during the last 15 years, with a shift from histamine(2)-receptor antagonists to proton-pump inhibitors (PPIs). From 1993 to 2000, expendi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::fac07f2c265599289539033fa20446e7
https://research.rug.nl/en/publications/b06f1e0f-a98a-4cf2-8ba5-d3ba16d8ea04
https://research.rug.nl/en/publications/b06f1e0f-a98a-4cf2-8ba5-d3ba16d8ea04